The impact of race on biochemical disease-free survival in early-stage prostate cancer patients treated with surgery or radiation therapy

Cancer progression, following radical prostatectomy, is distinguished by its biological or clinical aspects and is a controversial subject. As adjuvant therapy there is hormonal treatment and radiation therapy or a combination of both. The lack of standardization of the main pathological features of prostate cancer does not allow an accurate valuation of the results from the most important studies. A real efficacy in local or distant control seems to be certain, while the influence on disease-free survival is more uncertain. After a review of the most common options of treatment, the Authors present their results from 107 radical prostatectomies carried out between 1989 and 1994.

Download Full-text

Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients

Prostate Cancer and Prostatic Diseases ◽

10.1038/sj.pcan.4500600 ◽

2002 ◽

Vol 5 (3) ◽

pp. 212-218 ◽

Cited By ~ 25

Author(s):

A Desai ◽

H Wu ◽

L Sun ◽

I A Sesterhenn ◽

F K Mostofi ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Disease Free Survival ◽

Free Survival ◽

Disease Free

Download Full-text

125I Brachytherapy for Localized Prostate Cancer: A Single Institution Experience

Tumori Journal ◽

10.1177/030089161309900114 ◽

2013 ◽

Vol 99 (1) ◽

pp. 83-87 ◽

Cited By ~ 9

Author(s):

Alessia Guarneri ◽

Angela Botticella ◽

Andrea Riccardo Filippi ◽

Fernando Munoz ◽

Giancarlo Beltramo ◽

...

Keyword(s):

Prostate Cancer ◽

Multivariate Analysis ◽

Early Stage ◽

Disease Free Survival ◽

Localized Prostate Cancer ◽

Free Survival ◽

Genitourinary Toxicity ◽

Grade 3 ◽

Disease Free

Aims and background To evaluate the clinical outcome of a cohort of localized prostate cancer patients treated with 125I permanent brachytherapy at the University of Turin. Methods and study design A retrospective analysis was carried out on 167 consecutive patients with early stage prostate adenocarcinoma who underwent 125I brachytherapy between January 2003 and December 2010. A minimum follow-up of ≥12 months was mandatory for inclusion. Biochemical disease-free survival (defined on the basis of the ASTRO definition and the ASTRO-Phoenix definition) was chosen as the primary end point. Secondary end points were gastrointestinal and genitourinary toxicity (acute and late, defined according to the RTOG scale). Results With a median follow-up of 42 months (range, 13.5–90.7), biochemical disease-free survival at 3 and 5 years was respectively 91.1% and 85.7%, according to the ASTRO definition and 94.5% and 85.1% according to ASTRO-Phoenix definition (for statistical purposes, only the ASTRO definition was used). Hormone treatment and nadir PSA (cutoff of 0.35 ng/ml) were the only factors affecting biochemical disease-free survival both on univariate ( P = 0.02 and P = 0.001, respectively) and multivariate analysis (HR 0.024; P = 0.021 and HR 21.6; P = 0.006, respectively). Only 3.6% of patients experienced ≥grade 3 acute urinary toxicity and 5% ≥grade 3 late urinary toxicity. Prior transurethral prostate resection was the only independent predictor of grade 3 late urinary toxicity on multivariate analysis (HR 0.13; P = 0.009). Conclusions This mono-institutional series confirmed that brachytherapy is an effective and safe treatment modality for localized prostate cancer, with acceptable short- and long-term morbidity rates.

Download Full-text